Company intelligence / Profile preview

Prudentia Sciences

Cambridge, Massachusetts, United Statesprudentiasciences.com ↗

Ownership: Private
Employees: ~8
Development stage: Commercial

Overview

Prudentia Sciences has launched an AI-powered due diligence and valuation platform designed to accelerate biopharma dealmaking. The system integrates large language models, deep learning, and financial modeling to help pharma, biotech, and investors rapidly assess drug assets for acquisition or licensing. It aims to reduce diligence timelines from weeks to days by providing real-time simulations of key metrics like net present value (NPV), risk assessment, and scenario planning. The product is in commercial use with some investors as early adopters[2][5].

Industry: Biomedical IT and Biomedical Data Platforms

Partnerships

GVIaso VenturesVirtue

Beyond the preview

Go deeper on Prudentia Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prudentia Sciences.

Explore the full profile